Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.